Vitamin D supplementation and the risk of colds in patients with asthma

Loren C. Denlinger, Tonya S. King, Juan Carlos Cardet, Timothy Craig, Fernando Holguin, Daniel J. Jackson, Monica Kraft, Stephen P. Peters, Kristie Ross, Kaharu Sumino, Homer A. Boushey, Nizar N. Jarjour, Michael E. Wechsler, Sally E. Wenzel, Mario Castro, Pedro C. Avila

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Rationale: Restoration of vitamin D sufficiency may reduce asthma exacerbations, events that are often associated with respiratory tract infections and cold symptoms. Objectives: To determine whether vitamin D supplementation reduces cold symptom occurrence and severity in adults with mild to moderate asthma and vitamin D insufficiency. Methods: Colds were assessed in the AsthmaNet VIDA (Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness) trial, in which 408 adult patients were randomized to receive placebo or cholecalciferol (100,000 IU load plus 4,000 IU/d) for 28 weeks as add-on therapy. The primary outcome was cold symptom severity, which was assessed using daily scores on the 21-item Wisconsin Upper Respiratory Symptom Survey. Measurements and Main Results: A total of 203 participants experienced at least one cold. Despite achieving 25-hydroxyvitamin D levels of 41.9 ng/ml (95% confidence interval [CI], 40.1-43.7 ng/ml) by 12 weeks, vitamin D supplementation had no effect on the primary outcome: the average peak WURSS-21 scores (62.0 [95% CI, 55.1-68.9; placebo] and 58.7 [95% CI, 52.4-65.0; vitamin D]; P = 0.39). The rate of colds did not differ between groups (rate ratio [RR], 1.2; 95% CI, 0.9-1.5); however, among African Americans, those receiving vitamin D versus placebo had an increased rate of colds (RR, 1.7; 95% CI, 1.1-2.7; P = 0.02). This was also observed in a responder analysis of all subjects achieving vitamin D sufficiency, regardless of treatment assignment (RR, 1.4; 95% CI, 1.1-1.7; P = 0.009). Conclusions: Our findings in patients with mild to moderate asthma undergoing an inhaled corticosteroid dose reduction do not support the use of vitamin D supplementation for the purpose of reducing cold severity or frequency.

Original languageEnglish (US)
Pages (from-to)634-641
Number of pages8
JournalAmerican journal of respiratory and critical care medicine
Volume193
Issue number6
DOIs
StatePublished - Mar 15 2016
Externally publishedYes

Keywords

  • Asthma
  • Upper respiratory tract infection
  • Vitamin D
  • WURSS-21

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Denlinger, L. C., King, T. S., Cardet, J. C., Craig, T., Holguin, F., Jackson, D. J., ... Avila, P. C. (2016). Vitamin D supplementation and the risk of colds in patients with asthma. American journal of respiratory and critical care medicine, 193(6), 634-641. https://doi.org/10.1164/rccm.201506-1169OC

Vitamin D supplementation and the risk of colds in patients with asthma. / Denlinger, Loren C.; King, Tonya S.; Cardet, Juan Carlos; Craig, Timothy; Holguin, Fernando; Jackson, Daniel J.; Kraft, Monica; Peters, Stephen P.; Ross, Kristie; Sumino, Kaharu; Boushey, Homer A.; Jarjour, Nizar N.; Wechsler, Michael E.; Wenzel, Sally E.; Castro, Mario; Avila, Pedro C.

In: American journal of respiratory and critical care medicine, Vol. 193, No. 6, 15.03.2016, p. 634-641.

Research output: Contribution to journalArticle

Denlinger, LC, King, TS, Cardet, JC, Craig, T, Holguin, F, Jackson, DJ, Kraft, M, Peters, SP, Ross, K, Sumino, K, Boushey, HA, Jarjour, NN, Wechsler, ME, Wenzel, SE, Castro, M & Avila, PC 2016, 'Vitamin D supplementation and the risk of colds in patients with asthma', American journal of respiratory and critical care medicine, vol. 193, no. 6, pp. 634-641. https://doi.org/10.1164/rccm.201506-1169OC
Denlinger, Loren C. ; King, Tonya S. ; Cardet, Juan Carlos ; Craig, Timothy ; Holguin, Fernando ; Jackson, Daniel J. ; Kraft, Monica ; Peters, Stephen P. ; Ross, Kristie ; Sumino, Kaharu ; Boushey, Homer A. ; Jarjour, Nizar N. ; Wechsler, Michael E. ; Wenzel, Sally E. ; Castro, Mario ; Avila, Pedro C. / Vitamin D supplementation and the risk of colds in patients with asthma. In: American journal of respiratory and critical care medicine. 2016 ; Vol. 193, No. 6. pp. 634-641.
@article{fd1a3cdcda2d42a5afa3e840b4922264,
title = "Vitamin D supplementation and the risk of colds in patients with asthma",
abstract = "Rationale: Restoration of vitamin D sufficiency may reduce asthma exacerbations, events that are often associated with respiratory tract infections and cold symptoms. Objectives: To determine whether vitamin D supplementation reduces cold symptom occurrence and severity in adults with mild to moderate asthma and vitamin D insufficiency. Methods: Colds were assessed in the AsthmaNet VIDA (Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness) trial, in which 408 adult patients were randomized to receive placebo or cholecalciferol (100,000 IU load plus 4,000 IU/d) for 28 weeks as add-on therapy. The primary outcome was cold symptom severity, which was assessed using daily scores on the 21-item Wisconsin Upper Respiratory Symptom Survey. Measurements and Main Results: A total of 203 participants experienced at least one cold. Despite achieving 25-hydroxyvitamin D levels of 41.9 ng/ml (95{\%} confidence interval [CI], 40.1-43.7 ng/ml) by 12 weeks, vitamin D supplementation had no effect on the primary outcome: the average peak WURSS-21 scores (62.0 [95{\%} CI, 55.1-68.9; placebo] and 58.7 [95{\%} CI, 52.4-65.0; vitamin D]; P = 0.39). The rate of colds did not differ between groups (rate ratio [RR], 1.2; 95{\%} CI, 0.9-1.5); however, among African Americans, those receiving vitamin D versus placebo had an increased rate of colds (RR, 1.7; 95{\%} CI, 1.1-2.7; P = 0.02). This was also observed in a responder analysis of all subjects achieving vitamin D sufficiency, regardless of treatment assignment (RR, 1.4; 95{\%} CI, 1.1-1.7; P = 0.009). Conclusions: Our findings in patients with mild to moderate asthma undergoing an inhaled corticosteroid dose reduction do not support the use of vitamin D supplementation for the purpose of reducing cold severity or frequency.",
keywords = "Asthma, Upper respiratory tract infection, Vitamin D, WURSS-21",
author = "Denlinger, {Loren C.} and King, {Tonya S.} and Cardet, {Juan Carlos} and Timothy Craig and Fernando Holguin and Jackson, {Daniel J.} and Monica Kraft and Peters, {Stephen P.} and Kristie Ross and Kaharu Sumino and Boushey, {Homer A.} and Jarjour, {Nizar N.} and Wechsler, {Michael E.} and Wenzel, {Sally E.} and Mario Castro and Avila, {Pedro C.}",
year = "2016",
month = "3",
day = "15",
doi = "10.1164/rccm.201506-1169OC",
language = "English (US)",
volume = "193",
pages = "634--641",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "6",

}

TY - JOUR

T1 - Vitamin D supplementation and the risk of colds in patients with asthma

AU - Denlinger, Loren C.

AU - King, Tonya S.

AU - Cardet, Juan Carlos

AU - Craig, Timothy

AU - Holguin, Fernando

AU - Jackson, Daniel J.

AU - Kraft, Monica

AU - Peters, Stephen P.

AU - Ross, Kristie

AU - Sumino, Kaharu

AU - Boushey, Homer A.

AU - Jarjour, Nizar N.

AU - Wechsler, Michael E.

AU - Wenzel, Sally E.

AU - Castro, Mario

AU - Avila, Pedro C.

PY - 2016/3/15

Y1 - 2016/3/15

N2 - Rationale: Restoration of vitamin D sufficiency may reduce asthma exacerbations, events that are often associated with respiratory tract infections and cold symptoms. Objectives: To determine whether vitamin D supplementation reduces cold symptom occurrence and severity in adults with mild to moderate asthma and vitamin D insufficiency. Methods: Colds were assessed in the AsthmaNet VIDA (Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness) trial, in which 408 adult patients were randomized to receive placebo or cholecalciferol (100,000 IU load plus 4,000 IU/d) for 28 weeks as add-on therapy. The primary outcome was cold symptom severity, which was assessed using daily scores on the 21-item Wisconsin Upper Respiratory Symptom Survey. Measurements and Main Results: A total of 203 participants experienced at least one cold. Despite achieving 25-hydroxyvitamin D levels of 41.9 ng/ml (95% confidence interval [CI], 40.1-43.7 ng/ml) by 12 weeks, vitamin D supplementation had no effect on the primary outcome: the average peak WURSS-21 scores (62.0 [95% CI, 55.1-68.9; placebo] and 58.7 [95% CI, 52.4-65.0; vitamin D]; P = 0.39). The rate of colds did not differ between groups (rate ratio [RR], 1.2; 95% CI, 0.9-1.5); however, among African Americans, those receiving vitamin D versus placebo had an increased rate of colds (RR, 1.7; 95% CI, 1.1-2.7; P = 0.02). This was also observed in a responder analysis of all subjects achieving vitamin D sufficiency, regardless of treatment assignment (RR, 1.4; 95% CI, 1.1-1.7; P = 0.009). Conclusions: Our findings in patients with mild to moderate asthma undergoing an inhaled corticosteroid dose reduction do not support the use of vitamin D supplementation for the purpose of reducing cold severity or frequency.

AB - Rationale: Restoration of vitamin D sufficiency may reduce asthma exacerbations, events that are often associated with respiratory tract infections and cold symptoms. Objectives: To determine whether vitamin D supplementation reduces cold symptom occurrence and severity in adults with mild to moderate asthma and vitamin D insufficiency. Methods: Colds were assessed in the AsthmaNet VIDA (Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness) trial, in which 408 adult patients were randomized to receive placebo or cholecalciferol (100,000 IU load plus 4,000 IU/d) for 28 weeks as add-on therapy. The primary outcome was cold symptom severity, which was assessed using daily scores on the 21-item Wisconsin Upper Respiratory Symptom Survey. Measurements and Main Results: A total of 203 participants experienced at least one cold. Despite achieving 25-hydroxyvitamin D levels of 41.9 ng/ml (95% confidence interval [CI], 40.1-43.7 ng/ml) by 12 weeks, vitamin D supplementation had no effect on the primary outcome: the average peak WURSS-21 scores (62.0 [95% CI, 55.1-68.9; placebo] and 58.7 [95% CI, 52.4-65.0; vitamin D]; P = 0.39). The rate of colds did not differ between groups (rate ratio [RR], 1.2; 95% CI, 0.9-1.5); however, among African Americans, those receiving vitamin D versus placebo had an increased rate of colds (RR, 1.7; 95% CI, 1.1-2.7; P = 0.02). This was also observed in a responder analysis of all subjects achieving vitamin D sufficiency, regardless of treatment assignment (RR, 1.4; 95% CI, 1.1-1.7; P = 0.009). Conclusions: Our findings in patients with mild to moderate asthma undergoing an inhaled corticosteroid dose reduction do not support the use of vitamin D supplementation for the purpose of reducing cold severity or frequency.

KW - Asthma

KW - Upper respiratory tract infection

KW - Vitamin D

KW - WURSS-21

UR - http://www.scopus.com/inward/record.url?scp=84988697527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988697527&partnerID=8YFLogxK

U2 - 10.1164/rccm.201506-1169OC

DO - 10.1164/rccm.201506-1169OC

M3 - Article

C2 - 26540136

AN - SCOPUS:84988697527

VL - 193

SP - 634

EP - 641

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 6

ER -